摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(S)-N-[1-(4-乙基噻唑-2-基)-2-(4-硝基苯基)乙基]-4-氧代-4-苯基丁酰胺 | 1000394-70-6

中文名称
(S)-N-[1-(4-乙基噻唑-2-基)-2-(4-硝基苯基)乙基]-4-氧代-4-苯基丁酰胺
中文别名
——
英文名称
(S)-N-[1-(4-ethylthiazol-2-yl)-2-(4-nitrophenyl)ethyl]-4-oxo-4-phenylbutanamide
英文别名
N-[(1S)-1-(4-ethyl-1,3-thiazol-2-yl)-2-(4-nitrophenyl)ethyl]-4-oxo-4-phenylbutanamide
(S)-N-[1-(4-乙基噻唑-2-基)-2-(4-硝基苯基)乙基]-4-氧代-4-苯基丁酰胺化学式
CAS
1000394-70-6
化学式
C23H23N3O4S
mdl
——
分子量
437.519
InChiKey
XJNOZOYRXLSBCX-FQEVSTJZSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    683.7±55.0 °C(Predicted)
  • 密度:
    1.277±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4
  • 重原子数:
    31
  • 可旋转键数:
    9
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.26
  • 拓扑面积:
    133
  • 氢给体数:
    1
  • 氢受体数:
    6

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] METHODS FOR TREATING VASCULAR LEAK SYNDROME<br/>[FR] MÉTHODES DE TRAITEMENT DU SYNDROME DE FUITE VASCULAIRE
    申请人:AKEBIA THERAPEUTICS INC
    公开号:WO2010081172A1
    公开(公告)日:2010-07-15
    Disclosed are methods for treating Vascular Leak Syndrome. Further disclosed are methods for treating vascular leakage due to inflammatory diseases, inter alia, sepsis, lupus, irritable bowel disease. Yet further disclosed are methods for treating renal cell carcinoma and melanoma. Still further disclosed are methods for reducing metastasis of malignant cells and/or preventing the proliferation of carcinoma cells via spreading due to vascular leakage.
    揭示了治疗血管渗漏综合征的方法。进一步揭示了治疗由炎症性疾病引起的血管渗漏的方法,包括败血症、红斑狼疮、肠易激综合征等。还进一步揭示了治疗肾细胞癌和黑色素瘤的方法。更进一步揭示了通过血管渗漏引起的恶性细胞转移的方法,以及/或预防癌细胞通过扩散而增殖的方法。
  • METHODS FOR TREATING VASCULAR LEAK SYNDROME
    申请人:Shalwitz Robert
    公开号:US20140179693A1
    公开(公告)日:2014-06-26
    Disclosed are methods for treating Vascular Leak Syndrome. Further disclosed are methods for treating vascular leakage due to inflammatory diseases, inter alia, sepsis, lupus, inflammatory bowel disease. Yet further disclosed are methods for treating renal cell carcinoma and melanoma. Still further disclosed are methods for reducing metastasis of malignant cells and/or preventing the proliferation of carcinoma cells via spreading due to vascular leakage.
    揭示了治疗血管渗漏综合征的方法。进一步揭示了治疗由炎症性疾病引起的血管渗漏的方法,包括败血症、红斑狼疮、炎症性肠病等。还揭示了治疗肾细胞癌和黑色素瘤的方法。更进一步揭示了通过血管渗漏引起的恶性细胞转移的方法,以及预防癌细胞通过扩散而蔓延的方法。
  • Human protein tyrosine phosphatase inhibitors and methods of use
    申请人:Gray Lyle Jeffrey
    公开号:US20080004267A1
    公开(公告)日:2008-01-03
    The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-β) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising said human protein tyrosine phosphatase beta (HPTP-β) inhibitors, and to methods for regulating angiogenesis.
    本公开涉及有效作为人类蛋白酪氨酸磷酸酶β(HPTP-β)抑制剂的化合物,从而调节血管生成。本公开进一步涉及包含所述人类蛋白酪氨酸磷酸酶β(HPTP-β)抑制剂的组合物,以及用于调节血管生成的方法。
  • HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHOD OF USE
    申请人:Gray Jeffrey Lyle
    公开号:US20120077975A1
    公开(公告)日:2012-03-29
    The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-β) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising said human protein tyrosine phosphatase beta (HPTP-β) inhibitors, and to methods for regulating angiogenesis.
    本公开涉及有效作为人类蛋白酪氨酸磷酸酶β(HPTP-β)抑制剂的化合物,从而调节血管生成。本公开进一步涉及包含所述人类蛋白酪氨酸磷酸酶β(HPTP-β)抑制剂的组合物,以及调节血管生成的方法。
  • HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE
    申请人:Gray Jeffery Lyle
    公开号:US20110212951A1
    公开(公告)日:2011-09-01
    The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-β) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising said human protein tyrosine phosphatase beta (HPTP-β) inhibitors, and to methods for regulating angiogenesis.
    本公开涉及有效作为人类蛋白酪氨酸磷酸酶β(HPTP-β)抑制剂的化合物,从而调节血管生成。本公开还涉及包含所述人类蛋白酪氨酸磷酸酶β(HPTP-β)抑制剂的组合物,以及调节血管生成的方法。
查看更多